Combating Complexity: Partnerships in Personalized Medicine

• Corbett MF . The Outsourcing Revolution: Why it Makes Sense and How to Do it Right. Dearborn Trade Publishing, IL, USA (2004).
   Google Scholar
• Kutscher B . Expertise on call: annual outsourcing report shows providers of all sizes continue to pursue arrangements that offer savings for their revenue-strapped operations. Mod. Healthc.42(36) , 20, 22, 24–27 (2012).
   Google Scholar
• Pao W , HutchinsonKE. Chipping away at the lung cancer genome. Nat. Med.18(3) , 349–351 (2012).
   PubMed Web of Science ®Google Scholar
• Ciftlik AT , LehrHA, GijsMA. Microfluidic processor allows rapid HER2 immunohistochemistry of breast carcinomas and significantly reduces ambiguous (2+) read-outs. Proc. Natl Acad. Sci. USA110(14) , 5363–5368 (2013).
   PubMed Web of Science ®Google Scholar
• Vo BT , MortonD, KomaragiriS, MillenaAC, LeathC, KhanSA. TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation ofPI3K/AKT/mTOR pathway. Endocrinology154(5) , 1768–1779 (2013).
   PubMed Web of Science ®Google Scholar
• Jang S , AtkinsMB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol.14(2) , e60–e69 (2013).
   PubMed Web of Science ®Google Scholar
• Chen G , NoorA, KronenbergerP, TeugelsE, UmeloIA, De Grève J. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS ONE8(3) , e59708 (2013).
   PubMedGoogle Scholar
• Zhang YJ , GallisB, TayaM, WangS, HoRJ, SasakiT. pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members. PLoS ONE8(3) , e59086 (2013).
   PubMedGoogle Scholar
• Zitvogel L , KroemerG. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology1(8) , 1223–1225 (2012).
   PubMed Web of Science ®Google Scholar
• Kubo N , WuD, YoshiharaY, SangM, NakagawaraA, OzakiT. Co-chaperon DnaJC7/TPR2 enhances p53 stability and activity through blocking the complex formation between p53 and MDM2. Biochem. Biophys. Res. Commun.430(3) , 1034–1039 (2013).
   PubMed Web of Science ®Google Scholar
• Li W , TsenF, SahuD, BhatiaA, ChenM, MulthoffG, WoodleyDT. Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally. Int. Rev. Cell Mol. Biol.303 , 203–235 (2013).
   PubMed Web of Science ®Google Scholar
• Kampa-Schittenhelm KM , HeinrichMC, AkmutF, DöhnerH, DöhnerK, SchittenhelmMM. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol. Cancer12(1) , 19 (2013).
   PubMedGoogle Scholar
• Goncalves R , BoseR. Using multigene tests to select treatment for early-stage breast cancer. J. Natl Compr. Canc. Netw.11(2) , 174–182 (2013).
   PubMed Web of Science ®Google Scholar
• Dias MM , McKinnonRA, SorichMJ. Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics13(8) , 889–899 (2012).
   PubMed Web of Science ®Google Scholar
• Gerrard G , MudgeK, FoskettP et al. Fast-mode duplex qPCR for BCR–ABL1 molecular monitoring: innovation, automation, and harmonization. Am. J. Hematol. 87(7) , 717–720 (2012).
   PubMed Web of Science ®Google Scholar
• Carlson JJ , SullivanSD, GarrisonLP, NeumannPJ, VeenstraDL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy96(3) , 179–190 (2010).
   PubMed Web of Science ®Google Scholar
• Hornberger J , ChienR, KrebsK, HochheiserL. US insurance program‘s experience with a multigene assay for early-stage breast cancer. Am. J. Manag. Care17(5) , e194–e202 (2011).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Health Advances analysis of Pharmaprojects: pharmaceutical R&D pipeline intelligence. Informa UK Ltd, London, UK (2011). www.citeline.com
   Google Scholar
• My Cancer Genome. Molecular profiling of lung cancer (2013). www.mycancergenome.org/content/disease/lung-cancer
   Google Scholar
• Bonislawski A (Ed.). ProteoMonitor, GenomeWeb. Biodesix inks deal to test VeriStrat in Phase III clinical trial for Kadmon lung cancer drug (2012). www.genomeweb.com/proteomics/biodesix-inks-deal-test-veristrat-phase-iii-clinical-trial-kadmon-lung-cancer-dr
   Google Scholar
• National Science Foundation. National patterns of R&D resources (2009). www.nsf.gov/statistics/showpub.cfm?TopID=8&SubID=44
   Google Scholar
• Boroush M. US R&D spending resumes growth in 2010 and 2011 but still lags behind the pace of expansion of the national economy (2011). www.nsf.gov/statistics/infbrief/nsf13313
   Google Scholar
• Life Technologies Corporation. Life technologies to partner with Bristol-Myers Squibb for companion diagnostics development (2012). www.lifetechnologies.com/us/en/home/about-us/news-gallery/press-releases/2012/life-techologies-to-parter-with-bristol-myers-squibb-for-compaio.html
   Google Scholar
• US FDA. Draft guidance for industry and food and drug administration staff: in vitro companion diagnostic devices (2011). www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf
   Google Scholar
• Kahan JS, Tiedy-Stevenson SD, Payne KH. Medical Device Alert, Hogan Lovells. FDA issues draft guidance regarding in vitro companion diagnostic devices, an area of device regulation marked by ambiguity (2011). http://emailcc.com/rv/ff000212b94d8734bc1ed6e81748947b3ab99cee
   Google Scholar
• Personalized Medicine Coalition. Personalized medicine: an introduction. www.personalizedmedicinecoalition.org/sites/default/files/personalmed_backgrounder.pdf
   Google Scholar
• Health Advances analysis of Strategic Transactions – Deal Intelligence Database. Elsevier Business Intelligence (CT, USA) (2013). www.elsevierbi.com
   Google Scholar
• PrimeraDx. PrimeraDx announces commencement of product development collaboration with Eli Lilly and Company (2012). http://primeradx.com/news_events/press_releases/primeradx_announces_commencement_of_product_development_collaboration_with_eli_lilly_and_company
   Google Scholar
• Health Advances analysis of NCCN guidelines. www.nccn.org
   Google Scholar
• Response Genetics (2013). www.responsegenetics.com
   Google Scholar
• Gustavsen G, Phillips K, Pothier K. Health Advances, BIO. The reimbursement landscape for novel diagnostics (2011). www.healthadvances.com/pdf/novel_diag_reimbursement.pdf
   Google Scholar
• Quinn B. Foley Hoag LLP. The tempest continues, fee schedules in collision: Medicare and genomic tests prepare (2012). www.foleyhoag.com/NewsCenter/Publications/eBooks/The-Tempest-Continues-Fee-Schedules-in-Collision.aspx
   Google Scholar
• Pollack A. The New York Times. Pricing pills by results (2007). www.nytimes.com/2007/07/14/business/14drugprice.html?pagewanted=all&_r=0
   Google Scholar
• Watson P. Oncology Business Review. Risk-sharing schemes in oncology: future or fad (2010). www.oncbiz.com/documents/OBR_MAR10_RS(1).pdf
   Google Scholar
• Gustavsen G, Health Advances, Pothier K. Health Advances in vivo. How to earn the economic payback diagnostics companies deserve (2009). www.elsevierbi.com/publications/in-vivo/27/3/how-to-earn-the-economic-payback-diagnostics-companies-deserve
   Google Scholar
• Business Wire. Genzyme and Veracyte announce global co-promotion agreement to deliver personalized solution for thyroid patients (2012). www.businesswire.com/news/home/20120120005363/en/Genzyme-Veracyte-Announce-Global-Co-Promotion-Agreement-Deliver
   Google Scholar
• PR Newswire. Unilabs brings novel genomic test to breast cancer patients (2012). www.prnewswire.co.uk/news-releases/Unilabs-brings-novel-genomic-test-to-breast-cancer-patients-173651211.html
   Google Scholar
• MolecularHealth. SAP and MolecularHealth join forces to shape the future of personalized cancer treatment (2012). www.molecularhealth.com/press-releases/sap-and-molecularhealth-join-forces-to-shape-the-future-of-personlized-cancer-treatment/#more-940
   Google Scholar